Down's Syndrome people risk 'extinction' at the hands of science, fear and ignorance
By Tim Stanley,
The Telegraph
| 01. 18. 2016
Untitled Document
A painting hangs in the Metropolitan Museum of Art, New York called The Adoration of the Christ Child. Created in the 16th century by a Flemish artist, what stands out in this sublime presentation of the Nativity is the detail of the characters standing around the crib. Two of them, an angel and a shepherd, appear to have Down’s Syndrome.
This suggests that the condition has been around for a very long time, and it helps illuminate the early modern approach to disability. Religious art normally conformed to classical standards of beauty. By implication, the artist regarded people with Down’s as angelic. As, indeed, they are.
Unfortunately, society goes through peaks and troughs of sympathy towards the disabled – and we risk entering a darker age. The National Screening Committee has approved a simple blood test for Down’s Syndrome that in many ways is wonderful news. It should reduce the need for invasive testing procedures, which trigger around 350 cases of miscarriage every year.
But what do most women do when their baby tests positive for...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...